How to buy Cullinan Oncology stock (Cullinan Oncology)

Cullinan Oncology is a biotechnology business based in the US. Cullinan Oncology shares (CGEM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.02 – an increase of 3.62% over the previous week. Cullinan Oncology employs 85 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cullinan Oncology LLC stock

Buy Cullinan Oncology stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cullinan Oncology stock price (NASDAQ: CGEM)

Use our graph to track the performance of CGEM stocks over time.

Cullinan Oncology shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$12.02
52-week range	$10.00 - $30.19
50-day moving average more info button	$14.18
200-day moving average more info button	$17.81
Wall St. target price	$33.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.84

Is it a good time to buy Cullinan Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cullinan Oncology price performance over time

Historical closes compared with the close of $12.9 from 2024-12-26

1 week (2024-12-20)	11.21%
1 month (2024-11-27)	-1.45%
3 months (2024-09-27)	-24.96%
6 months (2024-06-28)	-26.03%

1 year (2023-12-28)	26.10%
2 years (2022-12-28)	27.47%
3 years (2021-12-28)	15.87
5 years (2019-12-24)	N/A

Cullinan Oncology financials

Gross profit TTM	$18.9 million
Return on assets TTM	-20.4%
Return on equity TTM	-26.53%
Profit margin	0%
Book value	$10.80
Market Capitalization more info button	$714.5 million

TTM: trailing 12 months

Cullinan Oncology share dividends

We're not expecting Cullinan Oncology to pay a dividend over the next 12 months.

You may also wish to consider:

• Amgen (AMGN.US) (3.61% forward annual dividend yield)

Have Cullinan Oncology's shares ever split?

Cullinan Oncology's shares were split on a 2:1 basis on 30 August 2009 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cullinan Oncology shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cullinan Oncology shares which in turn could have impacted Cullinan Oncology's share price.

Cullinan Oncology share price volatility

Over the last 12 months, Cullinan Oncology's shares have ranged in value from as little as $10 up to $30.1886. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cullinan Oncology's is -0.117. This would suggest that Cullinan Oncology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cullinan Oncology has bucked the trend.

To put Cullinan Oncology's beta into context you can compare it against those of similar companies.

• Amgen (AMGN.US): 0.599
• BeiGene (BGNE.US): 0.63
• XBiotech (XBIT.US): 1.413

Cullinan Oncology overview

Cullinan Therapeutics, Inc. , a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co.

Frequently asked questions

null
What percentage of Cullinan Oncology is owned by insiders or institutions?
Currently 4.495% of Cullinan Oncology shares are held by insiders and 118.387% by institutions. How many people work for Cullinan Oncology?
Latest data suggests 85 work at Cullinan Oncology. When does the fiscal year end for Cullinan Oncology?
Cullinan Oncology's fiscal year ends in December. Where is Cullinan Oncology based?
Cullinan Oncology's address is: One Main Street, Cambridge, MA, United States, 02142 What is Cullinan Oncology's ISIN number?
Cullinan Oncology's international securities identification number is: US2300311063